百威亞太(1876.HK)持續創新高 較IPO價已累漲20% 市值相當於3個潤啤
格隆匯10月9日丨自9月30日上市以來,百威亞太(1876.HK)股價持續上揚,不斷創出上市以來新高價,現報32.3港元,漲2.22%,盤中最高價為32.45港元,為上市以來新高,現價較招股價27港元漲19.6%,最新總市值4278億港元,相當於6個青島啤酒或3個華潤啤酒。麥格理首予百威亞太跑贏大市評級,目標價34港元;中信證券給予百威亞太目標價34港元,料受惠中國等市場消費升級。百威亞太將於2019年10月15日收市後獲納入恆生綜合指數及恆生消費品製造及服務業指數,10月16日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.